142 results on '"Hubank, Michael"'
Search Results
2. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
3. Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction
4. Genomic profile of advanced breast cancer in circulating tumour DNA
5. Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
6. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
7. Benefits for children with suspected cancer from routine whole-genome sequencing
8. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
9. Analysis of Gene Transcription in Cells Lacking DNA-PK Activity
10. Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations
11. A Phase 1/2 Study of STP938, a First in Class Inhibitor of CTP Synthase 1, in Patients with Relapsed/Refractory B or T Cell Lymphoma
12. Biochemical effects and molecular mechanisms of thyroid hormone action in the developing rat brain
13. A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot
14. DIPG-41. Multi-omic profiling of patient-derived subclones identifies aggressive cellular subpopulations in paediatric diffuse high-grade gliomas (PDHGGs)
15. Fitting Ordinary Differential Equations to Short Time Course Data
16. Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
17. Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers
18. Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura
19. Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial
20. Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients
21. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
22. Scalable and robust SARS-CoV-2 testing in an academic center
23. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
24. MODL-19. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL UP- OR DOWN-STREAM INHIBITION
25. MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG
26. Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study
27. EXTH-46. ARTIFICIAL INTELLIGENCE-BASED IDENTIFICATION OF COMBINED VANDETANIB AND EVEROLIMUS IN THE TREATMENT OF ACVR1-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA
28. DDRE-07. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL INHIBITION
29. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
30. Comparison of Three Assays for Identification of IDH Mutations in AML
31. Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1
32. Telomere elongation through hTERT immortalization leads to chromosome repositioning in control cells and genomic instability in Hutchinson-Gilford progeria syndrome fibroblasts, expressing a novel SUN1 isoform
33. Radiation-induced delayed cell death in a hypomorphic Artemis cell line
34. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.
35. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage
36. DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG
37. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing
38. Correction of scaling mismatches in oligonucleotide microarray data
39. Optimised ARID1A immunohistochemistry is an accurate predictor ofARID1Amutational status in gynaecological cancers
40. EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM
41. Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours
42. Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial
43. 529. Novel LTR-1 Lentiviral Vectors Are Fully Functional Following the Removal of HIV-1 Gag-RRE Sequences
44. STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage
45. Revealing Individual Signatures of Human T Cell CDR3 Sequence Repertoires with Kidera Factors
46. Dissection of a complex transcriptional response using genome‐wide transcriptional modelling
47. Fitting ordinary differential equations to short time course data
48. rHVDM – a fast and user-friendly R package to predict transcription factor targets from microarray time series data
49. Correction of scaling mismatches in oligonucleotide microarray data
50. Robustness of the p53 network and biological hackers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.